Fig. 5
From: Ionizable liposomal siRNA therapeutics enables potent and persistent treatment of Hepatitis B
Efficacy of RB-HBV008 in pAAV-HBV mouse model. a Treatment and sampling schedule of the study. b Grouping information. c–e Levels of HBsAg (c), viral DNA (d), and HBeAg (e) in circulation during the treatment course. f, g Expressions of HBsAg in the liver tissue were examined on day 7 (f) and day 28 (g). Data were shown as mean ± SEM. *P < 0.05, **P < 0.01 (two-tailed t test)
